Files and links (1)
Published, Version of Record (VoR)CC BY V4.0, Open
Journal article
Small Molecule Inhibitor Adjuvant Surfactant Therapy Attenuates Ventilator- and Hyperoxia-Induced Lung Injury in Preterm Rabbits
Frontiers in physiology, v 11, pp 266-266
09 Apr 2020
PMID: 32327998
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background
Invasive mechanical ventilation (IMV) has become one of the mainstays of therapy in NICUs worldwide, as a result of which premature babies with extremely low birth weight have been able to survive. Although lifesaving, IMV can result in lung inflammation and injury. Surfactant therapy is considered a standard of care in preterm infants with immature lungs. Recently, small molecule inhibitors like siRNAs and miRNAs have been used for therapeutic purposes. Ddit3 (CHOP), Ang2 and miR34a are known to be upregulated in experimental lung injury. We wanted to test whether inhibitors for these molecules (CHOP siRNA, Ang2 siRNA, and miR34a antagomir) if used alone or with a combination with surfactant (Curosurf(R)) would help in reducing ventilation and hyperoxia-induced injury in an experimental lung injury model.
Methods
Preterm rabbits born by cesarean section were intratracheally instilled with the three small molecule inhibitors with or without Curosurf(R) prior to IMV and hyperoxia exposure. Prior to testing the inhibitors in rabbits, these small molecule inhibitors were transfected in mouse lung epithelial cells (MLE12 and AECII) and delivered to neonatal mouse pups intranasally as a proof of concept that surfactant (Curosurf(R)) could be used as an effective vehicle for administration of such drugs. Survival, pulmonary function tests, histopathology, immunostaining, quantitative PCR and western blotting were done to see the adjuvant effect of surfactant with these three small molecule inhibitors.
Results
Our data shows that Curosurf(R) can facilitate transfection of small molecules in MLE12 cells with the same and/or increased efficiency as Lipofectamine. Surfactant given alone or as an adjuvant with small molecule inhibitors increases survival, decreases IMV and hyperoxia-induced inflammation, improves pulmonary function and lung injury scores in preterm rabbit kits.
Conclusion
Our study shows that Curosurf(R) can be used successfully as an adjuvant therapy with small molecule inhibitors for CHOP/Ang2/miR34a. In this study, of the three inhibitors used, miR34a inhibitor seemed to be the most promising compound to combat IMV and hyperoxia-induced lung injury in preterm rabbits.
Metrics
Details
- Title
- Small Molecule Inhibitor Adjuvant Surfactant Therapy Attenuates Ventilator- and Hyperoxia-Induced Lung Injury in Preterm Rabbits
- Creators
- Pragnya Das - Drexel UniversityTore Curstedt - Karolinska University HospitalBeamon Agarwal - GenomeRxUS, Secane, PA, United States.Varsha M. Prahaladan - Drexel UniversityJohn Ramirez - Yale UniversityShreya Bhandari - Drexel UniversityMansoor A. Syed - Yale UniversityFabrizio Salomone - R&D Department, Chiesi Farmaceutici, Parma, ItalyCostanza Casiraghi - R&D Department, Chiesi Farmaceutici, Parma, ItalyNicola Pelizzi - R&D Department, Chiesi Farmaceutici, Parma, ItalyVineet Bhandari - Drexel University
- Publication Details
- Frontiers in physiology, v 11, pp 266-266
- Publisher
- Frontiers Media Sa
- Number of pages
- 15
- Grant note
- Chiesi Farmaceutic S.p.a.; Chiesi Pharmaceuticals Inc Hartwell Foundation
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000529429400001
- Scopus ID
- 2-s2.0-85083897744
- Other Identifier
- 991019167552004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Physiology